NorTrials drives growth in Norwegian clinical trials

Peder Langeland Myhre, cardiologist and head of the NorTrials Centre for Cardiovascular Diseases. Professor at the University of Oslo and senior consultant at the Department of Cardiology, Oslo University Hospital, Rikshospitalet, and at the Department of Cardiology, Akershus University Hospital.

The author has completed the ICMJE form and declares the following conflicts of interest: he has been involved in clinical trials for and/or received speaker fees from Amarin, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, BMS, Eli Lilly, Gentian, Novartis, Novo Nordisk, Pharmacosmos, Roche, Sanofi, Us2.ai and Vifor, and has received research funding for investigator-initiated research from AstraZeneca via Akershus University Hospital.

Åslaug Helland, oncologist and head of research at the Cancer Clinic, Oslo University Hospital. Professor at the University of Oslo and head of the NorTrials Centre for Cancer.

The author has completed the ICMJE form and declares the following conflicts of interest: she has given talks for and participated in advisory meetings with AbbVie, Takeda, AstraZeneca, Roche, Pfizer, Janssen, Eli Lilly, BMS, Pierre Fabre, Bayer, MSD, Novartis, Merck, Sanofi and Medicover. Any fees were paid to Oslo University Hospital. She has also received research funding for investigator-initiated research from Roche, AstraZeneca, Novartis, Incyte, Eli Lilly, GSK, Johnson & Johnson, BeOne, Medicover, BMS, Ultimovacs and Illumina.

Kjell-Morten Myhr, professor and pro-rector at the University of Bergen and a senior consultant at the Department of Neurology, Haukeland University Hospital. He is deputy director of Neuro-SysMed – centre for clinical treatment research on neurological diseases, and head of the NorTrials Centre for Brain Health and Neurological Diseases.

The author has completed the ICMJE form and declares the following conflicts of interest: he has received speaker fees from Biogen, Novartis, Roche and Sanofi, been involved in clinical trials held by Biogen, Merck, Novartis, Otivio, Roche and Sanofi, and served on an advisory board for Alexion.

Jan Gunnar Skogås, CEO and head of department for the Centre for Innovation, Medical Devices and Technology (SIMUT) at St Olav's Hospital, Trondheim University/Norwegian University of Science and Technology (NTNU), head of the NorTrials Centre for Medical Devices, and head of the NorMIT (Norwegian Centre for Minimally Invasive Image Guided Therapy and Medical Technologies) national infrastructure, including the National Research Centre for Minimally Invasive and Image-Guided Diagnostics and Treatment (MiDT). He is also clinical director and head of department at Røros Hospital, St Olav's Hospital, Trondheim University.

The author has completed the ICMJE form and declares no conflicts of interest.

Thomas Langø, lead researcher at St Olav's Hospital, Trondheim University, and at SINTEF (Medical Technology Research Group). He is academic director of the NorTrials Centre for Medical Devices and of the National Research Centre for Minimally Invasive and Image-Guided Diagnostics and Treatment (MiDT). He is a member of the National Research Ethics Committee for Medicine and Health Sciences (NEM) and of the advisory board of the Centre for Innovation, Medical Devices and Technology (SIMUT) at St Olav's Hospital, Trondheim University/Norwegian University of Science and Technology NTNU.

The author has completed the ICMJE form and declares no conflicts of interest.

Rasmus Goll, professor and head of the Research Group for Gastroenterology and Nutrition at UiT The Arctic University of Norway and a senior consultant at the Medical Clinic, University Hospital of North Norway. He is head of the NorTrials Centre for Gastrointestinal Diseases and head of the Regional Committee for Medical Research Ethics Northern Norway (REK North).

The author has completed the ICMJE form and declares no conflicts of interest.

Jens Vikse, rheumatologist and head of the NorTrials Centre for Clinical Immunology. Senior consultant at Stavanger University Hospital and lecturer at the University of Stavanger. He serves on the board of the Norwegian Rheumatology Association and is a member of the EULAR Education Committee.

The author has completed the ICMJE form and declares the following conflicts of interest: he has received speaker fees and/or fees for participation in advisory boards for AbbVie, Amgen, Boehringer Ingelheim, GSK, Janssen/Johnson & Johnson, Merck, Novartis, Thermo Fisher and UCB. He is involved in clinical trials held by Chugai and Johnson & Johnson.

Signe Øien Fretland, cand.pharm. head of NorTrials Coordinating Unit, which is NorTrial's operational unit.

The author has completed the ICMJE form and declares no conflicts of interest.